BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Drugs such as imatinib, nilotinib, and dasatinib inhibit the phosphorylation activity of BCR-ABL and activation of downstream molecules, thus limiting the growth of CML cells [4].